IVAX receives approval in 11 European countries for generic nasal spray

By E. Janene Geiss

Philadelphia, Oct. 28 - IVAX Corp. announced Friday that it received final Mutual Recognition Procedure approval for Fluticasone nasal spray from the Medicine and Healthcare Products Regulatory Agency.

A generic form of Flixonase, or Flonase as its known in the United States, Fluticasone was approved for 11 countries across Europe, according to a company news release. Flonase is marketed by GlaxoSmithKline.

Officials said it expects the approval will be followed by a national marketing authorization, and the product will be launched in each country over the next few months.

There are no other known generic alternatives presently marketed in Europe, officials said.

Fluticasone already was approved in the United Kingdom and launched last May.

Miami-based IVAX Corp. develops, manufactures and markets branded and brand-equivalent pharmaceutical and veterinary products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.